Insight

Timothée Olivier: Our analysis tion about adjuvant use of CDK4/6 inhibitors in early breast cancer

A collage photo of Timothée Olivier and Vinay Prasad

May 24, 2024, 14:53

Timothée Olivier: Our analysis tion about adjuvant use of CDK4/6 inhibitors in early breast cancer

Vinay Prasad, Professor of Epidemiology and Biostatistics at the University of California, San Francisco, shared a post by Timothée Olivier, Medical Oncologist at HUG – Geneva University Hospitals on X, adding:

“Really important discussion about this new guideline.”

Quoting Timothée Olivier’s post:

“Journal of Clinical Oncology updated their recommendation about adjuvant use of CDK4/6 inhibitors in early breast cancer.

Are patients protected enough?

See our analysis below.”

Timothée Olivier

Additional information.
Source: Vinay Prasad/X and Timothée Olivier/X

Breast Cancer cancer CDK4/6 inhibitors Geneva University Hospitals Journal of Clinical Oncology OncoDaily Oncology Timothée Olivier University of California Vinay Prasad

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage